Navigation Links
Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
Date:11/2/2012

NEW BRUNSWICK, N.J., Nov. 2, 2012 /PRNewswire/ -- Janssen and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Saturday, November 10, at approximately 5:00 p.m., Eastern Time, to coincide with the American College of Rheumatology (ACR) Annual Meeting being held in Washington, D.C. 

The presentation will highlight new, pivotal Phase 3 study findings, including;

  • Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase 3 Trial
  • Ustekinumab in Active Psoriatic Arthritis Including Patients Previously Treated with Anti-TNF Agents: Results of a Phase 3, Multicenter, Double-blind, Placebo-controlled Study; Continued Improvement of Signs and Symptoms in Ustekinumab-treated Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-blind, Placebo-controlled Study

The pre-recorded webcast with management from the Company's Janssen pharmaceutical subsidiaries, will provide an update on the Immunology rheumatology pipeline and commercial franchise.

The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations."


'/>"/>
SOURCE Johnson & Johnson
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
2. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
3. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
4. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
5. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
6. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
7. Johnson & Johnson Postpones Medical Devices & Diagnostics Review
8. Johnson & Johnson to Host Medical Devices & Diagnostics Review
9. Johnson & Johnson Announces Plans to Establish Innovation Centers
10. Robert G. Savage, Former Worldwide Chairman, Johnson & Johnsons Pharmaceuticals Group, Joins Board of Nuovo Biologics, LLC
11. Johnson Health Tech Statement on Lance Armstrong
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... the United States , 54 percent ... BRAF inhibitor Tafinlar for BRAF -mutation-positive unresectable ... have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among current ... (42 percent and 43 percent, respectively) expects to ...
(Date:9/18/2014)... 18, 2014  KIYATEC announced today that it ... Innovation Research (SBIR) Phase II Contract from the ... institutes and centers that comprise the National Institutes ... two year award, KIYATEC will expand its 3D ... the forefront of cancer therapy strategies: 1) cancer,s ...
(Date:9/18/2014)... MEETING, Pa. , Sept. 18, 2014 ... trial solutions, was recognized as the Disruptive ... for its ePharmaONE cloud-based eClinical platform. This ... and electronic trial master file (eTMF), a ... solution, and ePharmaSolutions, ReferralPlus+ patient screening and ...
Breaking Medicine Technology:At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 3
... NORTHFIELD, Ill., Aug. 22, 2011 The latest developments ... be featured topics when more than 1,000 pathologists gather ... for the annual scientific meeting of the College ... THE Pathologists, Meeting™ will highlight advances in digital ...
... SANTA ANA, Calif., Aug. 22, 2011 Abbott (NYSE: ... expanded its Healon® family of ophthalmic viscosurgical devices (OVDs) ... The  clear, viscous, low molecular weight dispersive ... in cataract extraction, intraocular lens (IOL) implantation, corneal transplantation, ...
Cached Medicine Technology:Pathologists Gather to Focus on Advances in Molecular Testing, Digital Imaging, and Biospecimens 2Pathologists Gather to Focus on Advances in Molecular Testing, Digital Imaging, and Biospecimens 3Abbott Receives CE Mark for Healon EndoCoat Protective Gel for Cataract Surgery 2
(Date:9/18/2014)... It is that time of year – ... Once again, Evensong Spa at Heidel House ... services at a special $50 rate Oct. 20 through Nov. ... Hotels & Resorts , is the only Wisconsin destination spa ... embrace health and wellness by experiencing affordable spa and wellness ...
(Date:9/18/2014)... Study after study has proven it true: exercise is ... Pennsylvania scientists suggests that exercise may have an added ... performed in a mouse model of melanoma, found that ... alone. , Joseph Libonati, an associate professor in ... of Innovative and Translational Nursing Research, was the senior ...
(Date:9/18/2014)... Lake City, UT (PRWEB) September 18, 2014 ... North America will be recognizing their shared fundraising impact ... on Thursday, Sept. 25. , The first-ever Dance Marathon ... more than $20 million projected to be raised by ... their community’s CMN Hospital. Donations generated through Dance Marathon ...
(Date:9/18/2014)... -- don,t worry, it,s a good thing! As scientists ... are bad. Many active enzymes and bacteria are merely ... an important part of our digestive system or can ... , an opportunistic yeast pathogen and model organism for ... personal ecosystem. However, when our immune system is stressed ...
(Date:9/18/2014)... ANGELES (September 18, 2014) The National Institutes ... funding from a four-year, $1.3 million grant to the ... in the research and development of a vaccine to ... and Methicillin-resistant Staphylococcus aureus (MRSA). , ... of the NIH awarded the grant to LA BioMed ...
Breaking Medicine News(10 mins):Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... Use of anesthesia providers to monitor sedation during screening ... from 2003 to 2009 in the United States, with ... not need this service, according to a new RAND ... as $1.1 billion spent annually on anesthesia services for ...
... March 20 (HealthDay News) -- Calculating the difference ... right arms might help predict a patient,s odds of ... Researchers found that people with high blood pressure whose ... higher risk of cardiovascular death over 10 years. ...
... (HealthDay News) -- The northeastern United States may see a significant ... The reason is that oak trees produced relatively few acorns ... years for the acorn crop. But the small crop means trouble ... had a boom in acorns, followed by a boom in mice. ...
... Reporter , TUESDAY, March 20 (HealthDay News) -- ... own stem cells may someday replace or reduce the ... Six months after receiving a kidney transplant, only ... stem cells experienced rejection compared with almost 22 percent ...
... failure and endocrine tumors are among the suspects causing ... relievers in your medicine cabinet be the culprit? ... Sackler Faculty of Medicine and the Sheba Medical Center, ... of hypertension, which is a major risk factor for ...
... March 20 (HealthDay News) -- Seeing a baby,s face triggers ... reward and planning movement, a finding researchers say may indicate ... Researchers observed this pattern in adults who didn,t know the ... "These adults have no children of their own. Yet images ...
Cached Medicine News:Health News:Use of anesthesia providers during GI procedures is growing, but may be unnecessary 2Health News:Blood Pressure Variance Between Arms Points to Heart Risk 2Health News:Northeast U.S. Should Brace for Spike in Lyme Disease: Expert 2Health News:Stem Cell Therapy Could Boost Kidney Transplant Success: Study 2Health News:Stem Cell Therapy Could Boost Kidney Transplant Success: Study 3Health News:Stem Cell Therapy Could Boost Kidney Transplant Success: Study 4Health News:Pain relievers could be spiking your blood pressure 2Health News:Infants' Faces Trigger Caregiving Impulse in Adults' Brains 2
... Flexible biopsy forceps are extremely delicate ... incompetent repair source, they can easily be ... turn, damage your endoscopes. , On the ... flexible biopsy forceps can have a virtually ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
... With our factory-quality repairs, physicians know ... why more hospitals turn to Mobile Instrument ... We offer a full line of carbide ... our four-way quality control process. You'll enjoy ...
Inquire...
Medicine Products: